A Study Comparing Effect Of Direct Acting Antiviral (DAA) Regimen And Interferon-a/Ribavirin Therapy On Transcriptional Changes In Patients With Chronic Hepatitis-C Infection.

Trial Profile

A Study Comparing Effect Of Direct Acting Antiviral (DAA) Regimen And Interferon-a/Ribavirin Therapy On Transcriptional Changes In Patients With Chronic Hepatitis-C Infection.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jan 2017

At a glance

  • Drugs Asunaprevir/becabluvir/daclatasvir (Primary) ; Peginterferon alfa; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 26 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top